^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/12/2020
Excerpt:
Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.
